## **Supplementary Table 1**

Vaccinee cohorts	Vaccinees (all)	Without prior infection	With prior infection
Ad26.COV2.S (Janssen) - 1 dose			
Number	20	7	13
Age (y) (median, IQR)	41 [32-52]	44 [32-54]	41 [32-48]
Gender (% female)	75%	71.4%	76.9%
With co-morbidities (n, %)	6/20 (30%)	2/7 (28.6%)	4/13 (30.8%)
Days since last vaccine dose (median, IQR)	28 [28-32]	31 [28-34]	28 [27-29]
Months since COVID episode (median, IQR)	-	na	3 [2-6]*
Ad26.COV2.S (Janssen) - 2 doses			
Number	20	6	14
Age (y) (median, IQR)	38 [33-56]	58 [36-62]	36 [32-44]
Gender (% female)	75%	83.3%	71.4%
With co-morbidities (n, %)	9/20 (45%)	4/6 (66.7%)	5/14 (35.7%)
Days since last vaccine dose (median, IQR)	22 [21-24]	23 [21-25]	22 [21-23]
Months since COVID episode (median, IQR)	-	na	15 [11-18]
BNT162b2 (Pfizer) - 2 doses			
Number	15	9	6
Age (y) (median, IQR)	53 [45-71]	53 [41-74]	57 [44-66]
Gender (% female)	53.3%	44.4%	66.7%
With co-morbidities (n, %)	9/15 (60%)	4/9 (44.4%)	5/6 (83.3%)
Days since last vaccine dose (median, IQR)	33 [22-48]	46 [23-65]	27 [20-38]
Months since COVID episode (median, IQR)	-	na	14 [13-15]

## **Supplementary Table 1: Clinical characteristics of vaccinee cohorts.** Co-morbidities include: asthma, hypertension, obesity or diabetes mellitus.

<sup>\*:</sup> data regarding time post Covid-19 infection were available for only 6 out of the 13 participants who received 1 dose of Ad26-COV.S.

Convalescent cohort (unvaccinated)				
Number	15			
Age (y) (median, IQR)	39 [35-49]			
Gender (% female)	12%			
With co-morbidities (n, %)	6/15 (40%)			
Months since COVID episode (median, IQR)	1.4 [1.3-6]			

Supplementary Table 2: Clinical characteristics of convalescent COVID-19 patients. Co-morbidities include: asthma, hypertension, obesity or diabetes mellitus.

Hospitalized COVID-19 cohort	Total	Wave 1 (Ancestral)	Wave 2 (Beta)	Wave 3 (Delta)	Wave 4 (Omicron)
Number	68	17	16	16	19
Age (y) (median, range)	53 [39-64]	55 [41-62]	64 [53-68]	49 [37-63]	47 [35-60]
Gender (% female)	47%	29.4%	56.2%	56.2%	47.4%
With co-morbidities (n, %)	53/68 (77.9%)	11/17 (64.7%)	15/16 (93.7%)	13/16 (81.2%)	14/19 (73.7%)
Day since PCR+ (median, range)	4 [2-8]	2 [1-3.5]	5 [2-10]	6 [2-10]	4 [3-6]
Severe COVID-19 (WHO ≥5)	26/68 (38.2%)	7/17 (41.2%)	1/16 (6.25%)	9/16 (56.2%0	9/19 (47.4%)

## **Supplementary Table 3: Clinical characteristics of hospitalized COVID-19 patient cohort.**

Co-morbidities include: asthma, hypertension, obesity or diabetes mellitus. Severe COVID-19 was defined based on oxygen therapy requirement according to the WHO ordinal scale scoring system (O<sub>2</sub> via high flow to extracorporeal membrane oxygenation).